A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.

Launched by QIANFOSHAN HOSPITAL · Jan 12, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how effective a combination of treatments is for patients with intermediate and advanced liver cancer. Specifically, it compares the standard treatment called TACE (Transarterial Chemoembolization) alone to TACE used alongside newer therapies like immunotherapy and targeted therapy. The goal is to see if adding these therapies can improve outcomes for patients.

To be eligible for this trial, participants need to be at least 18 years old and have been diagnosed with primary liver cancer, which can be confirmed through a biopsy or specific tests. They should also have a certain level of liver function and be in stages B or C of the disease, with a good overall health status. Participants can expect to receive either the standard treatment or the combination treatment and will be monitored closely throughout the study. It's important to note that individuals with certain serious health issues or other types of cancer may not qualify. This study is currently looking for participants, so if you or someone you know meets the criteria, it could be an opportunity to contribute to important research in liver cancer treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ≥18 years old, both men and women
• • primary liver cancer confirmed by liver biopsy or history of hepatitis B, AFP, and typical imaging findings
• • patients with liver function Child-Pugh A or B (≤8 points)
• • BCLC stage B and stage C
• • expected survival time ≥8 weeks
• • patients with generally good performance status (ECOG PS score 0 or 1)
• Exclusion Criteria:
• • The patient's key data is missing
• • liver metastatic cancer confirmed by histology or cytology
• • patients who interrupt treatment due to intolerance of adverse drug reactions
• • combined with primary malignant tumors of other organs within 5 years; combined with other serious diseases, such as severe heart disease, renal insufficiency, severe infection, bleeding, etc.
• • combined with systemic infection, autoimmune disease, or other types of tumors; previous allogeneic bone marrow transplantation or solid organ transplantation
• • study participants known to have mental illness
• • situations such as drug use or substance abuse